Margarita Reboredo

Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer

Manuel Valladares‐Ayerbes, Margarita Reboredo, Vanessa Medina-Villaamil et al. · Journal of Translational Medicine · 2012 · 153 citations · Full text

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2

Teresa Macarulla, Roberto Pazo-Cid, Carmen Guillén‐Ponce et al. · Journal of Clinical Oncology · 2018 · 89 citations

Evaluation of the Adenocarcinoma-Associated Gene AGR2 and the Intestinal Stem Cell Marker LGR5 as Biomarkers in Colorectal Cancer

Manuel Valladares‐Ayerbes, M. Blanco, Margarita Reboredo et al. · International Journal of Molecular Sciences · 2012 · 85 citations · Full text

Crc Patients, Pathology, Cancer Biology +16

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

Enrique Aranda, Pilar García‐Alfonso, Manuel Benavides et al. · European Journal of Cancer · 2018 · 78 citations

Phase Ii, Macro2 Ttd Study, First-line Mfolfox +9

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

Fernando Rivera, C. Romero, Paula Jiménez‐Fonseca et al. · Cancer Chemotherapy and Pharmacology · 2019 · 63 citations · Full text